These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 7552232)

  • 1. PDA comments: SUPAC-IR, ICH Q1C, FDA draft guideline. Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1995; 49(4):152-6. PubMed ID: 7552232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Investigators' Brochure: a comparison of the draft international conference on harmonisation guideline with current Food and Drug Administration requirements.
    Cocchetto DM
    Qual Assur; 1995 Dec; 4(4):240-6. PubMed ID: 8890349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PDA response. "Guideline for submitting documentation for sterilization process validation in applications for human and veterinary drug products". Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1995; 49(2):62-6. PubMed ID: 7780746
    [No Abstract]   [Full Text] [Related]  

  • 4. PDA presentation at FDA Open Conference on Sterile Drug Manufacturing. Parenteral Drug Association.
    J Pharm Sci Technol; 1994; 48(1):4-6. PubMed ID: 8004417
    [No Abstract]   [Full Text] [Related]  

  • 5. PDA comments: ICH Q6A; draft guidance on specifications. Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1998; 52(5):232-3. PubMed ID: 9846071
    [No Abstract]   [Full Text] [Related]  

  • 6. Some further comments on aseptic processing guidance, or the fool on the hill: Parenteral Drug Association.
    Agalloco J
    PDA J Pharm Sci Technol; 2003; 57(5):324-30. PubMed ID: 14677624
    [No Abstract]   [Full Text] [Related]  

  • 7. PDA comments on USP in-process revision <1116> microbiological evaluation of clean rooms and other controlled environments. Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1995; 49(6):264-6. PubMed ID: 8581456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PDA comments on draft guidance for industry on changes to an approved NDA or ANDA. Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1999; 53(5):264-72. PubMed ID: 10754723
    [No Abstract]   [Full Text] [Related]  

  • 9. International Conference on Harmonisation; Guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the International Conference on Harmonisation Regions; Annex 8 on Sterility Test General Chapter; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Dec; 74(244):68068-9. PubMed ID: 20336863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDA comments. "Review of general biologics licensing regulations". Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1995; 49(2):59-61. PubMed ID: 7780745
    [No Abstract]   [Full Text] [Related]  

  • 11. Comments on the FDA draft guidance on biosimilar products.
    Chow SC; Endrenyi L; Lachenbruch PA
    Stat Med; 2013 Feb; 32(3):364-9. PubMed ID: 22903309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PDA comments on draft guidance for industry, ANDAs: blend uniformity. Parenteral Drug Association.
    PDA J Pharm Sci Technol; 2000; 54(1):2-5. PubMed ID: 10778301
    [No Abstract]   [Full Text] [Related]  

  • 13. PDA comments to USP on 'proposed changes to <71> sterility tests'.
    Fry EM
    PDA J Pharm Sci Technol; 1996; 50(2):69-78. PubMed ID: 8935773
    [No Abstract]   [Full Text] [Related]  

  • 14. Regulatory Forum Opinion Piece: Review of FDA Draft Guidance Testicular Toxicity-Evaluation during Drug Development Guidance for Industry.
    Hukkanen RR; Halpern WG; Vidal JD
    Toxicol Pathol; 2016 Oct; 44(7):927-30. PubMed ID: 27357192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PDA comments on "EU guide to good manufacturing practice; annex on the manufacture of sterile medicinal products". Parenteral Drug Association.
    PDA J Pharm Sci Technol; 1996; 50(3):138-43. PubMed ID: 8696775
    [No Abstract]   [Full Text] [Related]  

  • 16. International Conference on Harmonisation; Guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the International Conference on Harmonisation Regions; Annex on Test for Extractable Volume of Parenteral Preparations General Chapter; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jan; 74(6):908-9. PubMed ID: 20333832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PDA comments on proposed rule: supplements and other changes to an approved application. Parenteral Drug Applications.
    PDA J Pharm Sci Technol; 1999; 53(5):273-6. PubMed ID: 10754724
    [No Abstract]   [Full Text] [Related]  

  • 18. International Conference on Harmonisation; Guidance on Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the International Conference on Harmonisation Regions; Annex 5 on Disintegration Test General Chapter; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Dec; 74(245):68270-1. PubMed ID: 20344862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDA response. FDA advance notice of proposed rulemaking on electronic identification/signatures. Parenteral Drug Association.
    J Parenter Sci Technol; 1993; 47(1):4-8. PubMed ID: 8445499
    [No Abstract]   [Full Text] [Related]  

  • 20. Draft guidance for industry; exports and imports under the FDA Export Reform and Enhancement Act of 1996--FDA. Notice.
    Fed Regist; 1998 Jun; 63(113):32219-34. PubMed ID: 10180275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.